Free press releases distribution network?

Agency / Source: inGenious Targeting Laboratory, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



inGenious Targeting Laboratory Scores Contracts for Use of Innovative TruHumanization™ Technology - inGenious Targeting Laboratory, a leading global provider of genetically modified mouse models, announced today that they have solidified multiple contracts to create mouse models using their exclusive TruHumanization™ technology
inGenious Targeting Laboratory Scores Contracts for Use of Innovative TruHumanization™ Technology

 

PRZOOM - /newswire/ - Ronkonkoma, NY, United States, 2014/08/20 - inGenious Targeting Laboratory, a leading global provider of genetically modified mouse models, announced today that they have solidified multiple contracts to create mouse models using their exclusive TruHumanization™ technology.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

TruHumanization™ technology by inGenious has generated much interest from a variety of companies and institutes. These contracts come just two weeks after the release of this innovative technology platform.
As the recent spike in translational research continues, there has been an increased need for animal models that better mimic phenotypes seen in humans. Traditional methods of creating humanized mouse models manipulate only the coding regions of the genes of interest, and therefore are limited in their true representation of human gene function. The Company’s exclusive TruHumanization™ technology offers a solution to the challenges presented by standard methods to humanize the mouse. This technology utilizes large BACs, enabling inGenious to replace the entire mouse gene with the entire human gene sequence including promoter, intron, exon, and regulatory sequences. This leads to more faithful gene regulation and processing as well as the potential to perform functional and regulatory studies on multiple transcripts.

President Paul J. Sheiffele believes this technology will provide scientists with more accurate models for studying human disease, setting inGenious Targeting Laboratory apart from other mouse model companies.

About inGenious Targeting Laboratory

Established in 1998, inGenious Targeting Laboratory (iTL) exclusively creates mice whose genetic make-up is tailored to the client’s research needs. Clients retain all intellectual property rights to their projects. A full range of project capabilities are available including: conventional and conditional knockouts, knockin models (humanized, inducible, reporter gene/cassette insertion, point mutations), as well as novel approaches for generating customized mouse models. Projects are initiated immediately upon completion of design parameters and progress to completion on-site in the USA, under the supervision of a dedicated scientific Project Manager. iTL is located in Ronkonkoma, New York.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: inGenious Targeting Laboratory, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


inGenious Targeting Laboratory Scores Contracts for Use of Innovative TruHumanization™ Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tegan Ryan - GeneTargeting.com 
631-681-5653 inquiry[.]genetargeting.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any inGenious Targeting Laboratory, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From inGenious Targeting Laboratory, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today